MONET1-MOtesanib NSCLC Efficacy and Tolerability Study
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer.
Sponsor: Amgen
Terminated
Amgen discontinued the development of AMG706 because 20050201 did not meet its primary objective.
Other terminated trials from Amgen
Other Non-Small Cell Lung Cancer trials with similar outcome
This PHASE3 trial investigates Non-Small Cell Lung Cancer and is currently terminated or withdrawn. Amgen leads this study, which shows 11 recorded versions since 2007 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Apr 2022 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Jul 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.